Other Deal Trends 2026: Activity Surges 3400% in 6 Months

Thirty-four deals. That is the number of transactions classified under "other" deal activity recorded between February 21 and August 21, 2026 — up from exactly zero in the prior six-month window (August 21, 2025 to February 21, 2026). A 3400% surge does not happen because a category suddenly becomes interesting; it happens because the category's boundaries have expanded to absorb deal types that legacy taxonomies never anticipated. What we are witnessing in other deal trends 2026 is the emergence of a shadow pipeline — platform technology deals, enabling infrastructure licenses, and cross-sector collaborations that do not fit neatly into traditional therapeutic-area classifications but now command multi-billion-dollar valuations.

The Data — Other Deal Activity, Period over Period

The jump from zero to 34 is not a statistical artifact. It reflects a real structural shift in what pharma is willing to pay for — and how deals are being categorized as enabling-technology transactions fall outside conventional oncology, immunology, or CNS buckets. When a single deal in this space carries an $11.3 billion total deal value, the category demands serious attention from every BD team tracking Deal Benchmarks.

What's Driving the Trend

Three forces converge to explain this spike in other licensing 2026 activity. First, platform desperation. Big Pharma's pipeline replenishment strategy has shifted from asset-level in-licensing to platform-level acquisitions. The logic is straightforward: buying a single molecule addresses one indication; buying the platform that generates molecules addresses a portfolio gap for a decade. Bio-Techne's deal with Merck KGaA — valued at $11.3 billion — is the clearest example. This is not a bet on one drug candidate. It is a bet on an entire technology stack that enables protein engineering, cell analysis, and bioprocessing at scale. Deals like this defy traditional therapeutic-area classification because the platform's value lies precisely in its applicability across multiple TAs.

Second, AI-native drug design is forcing new deal architectures. Generate: Biomedicines' collaboration with Novartis, announced June 28, represents the latest in a growing pattern of partnerships where the asset being licensed is not a compound but a computational engine. These deals cannot be classified as oncology or immunology because the generative model produces candidates across therapeutic areas. The deal structures themselves are novel — often involving milestone-triggered access to successive programs rather than traditional upfront-plus-royalties frameworks. Traditional deal databases struggle to categorize them, pushing volume into the "other" bucket.

Third, geographic diversification is accelerating cross-border deal types that defy legacy classification. YaoPharma's $2.05 billion TDV agreement with Pfizer — with $150 million upfront — reflects Big Pharma's aggressive push into China-originated assets and regional commercial partnerships. When the strategic rationale is geographic market access rather than therapeutic novelty, these transactions often land outside standard TA categories. The $150 million upfront on a $2.05 billion TDV implies a roughly 7.3% upfront-to-TDV ratio — lean by oncology standards but consistent with partnerships where the value proposition is regional infrastructure rather than clinical-stage molecules.

Notable Deals

The Bio-Techne/Merck KGaA transaction dominates this dataset and arguably distorts it — the $11.3 billion TDV represents an outright acquisition-scale commitment for a tools and reagents company. Multiple filings on different dates suggest a phased or amended deal structure, which itself is instructive: mega-deals in the platform technology space are being structured with staggered closings and regulatory-contingent tranches rather than single-shot acquisitions. This is a direct response to antitrust scrutiny that has slowed conventional M&A timelines by 4–6 months on average over the past two years.

The Generate: Biomedicines/Novartis deal, while undisclosed in financial terms, matters for a different reason. It validates the AI-native platform as a distinct asset class worthy of Big Pharma partnership. Novartis has been disciplined about AI collaborations — this is not a spray-and-pray strategy. When undisclosed deals from credible counterparties land in the "other" category, it signals that the most strategically sensitive transactions are exactly the ones that resist traditional classification.

YaoPharma's Pfizer deal is the outlier that proves the geographic-access thesis. A $150 million upfront for a Chinese pharma company licensing to Pfizer suggests Pfizer is buying distribution infrastructure and regulatory pathways, not just molecules. The $2.05 billion TDV implies substantial commercial milestones tied to China market performance — a structure that has become increasingly common as Big Pharma hedges against US pricing pressure with APAC revenue diversification.

What This Means for BD Teams Right Now

If you are a platform technology company — tools, reagents, AI-native drug design, bioprocessing — you are sitting in a seller's market that did not exist 12 months ago. The Bio-Techne deal has reset valuation expectations for the entire sector. BD teams at enabling-technology companies should be benchmarking against this transaction immediately using the Ambrosia calculator to understand where their TDV should land relative to revenue multiples and technology breadth. Waiting for "more data points" is a mistake; the window where Big Pharma is willing to pay platform premiums will narrow as 2026 progresses and integration challenges from early deals become visible.

If you are a Big Pharma BD team, move fast but structure defensively. The staggered closing approach in the Bio-Techne deal is a template worth copying — it gives you regulatory off-ramps and lets you validate technology integration before committing full capital. Avoid single-tranche acquisitions of platform assets until you have proof-of-concept from at least one therapeutic application. Option-based structures with escalating commitment — the kind Generate: Biomedicines likely negotiated with Novartis — give you exposure to the upside without betting the balance sheet on unproven computational platforms.

For biotech founders whose assets do not fit clean therapeutic-area categories: stop trying to force your deal into an oncology or immunology framework. The data shows that pharma is now actively seeking assets that span categories. Position your platform as a portfolio solution, not a single-asset play. The valuation premium is in breadth. Use Deal Benchmarks to identify comparable platform transactions and anchor your term sheet accordingly.

The "other" category is no longer a dumping ground for miscellaneous deals. It is the fastest-growing segment in biopharma partnering — and the deals landing here are among the largest in the industry.

Benchmark your deal against current market rates. Whether you are pricing a platform technology license, an AI collaboration, or a cross-border commercial partnership, the Ambrosia calculator gives you real-time comparables drawn from verified transaction data — including the deals driving this 3400% surge.